{"id":948989,"date":"2026-04-06T06:21:04","date_gmt":"2026-04-06T10:21:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/"},"modified":"2026-04-06T06:21:04","modified_gmt":"2026-04-06T10:21:04","slug":"shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/","title":{"rendered":"Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law"},"content":{"rendered":"<h2>\nBFA Law is investigating ADMA Biologics after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws.<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>NEW YORK, April  06, 2026  (GLOBE NEWSWIRE) &#8212; Leading securities law firm <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vWQTSos8Do9-uN05R69Ix-LMv8uk08mX6X3C3pNaKgjNJbtZ9NazhOyebO4mc9Oq0ToWxT6sPBPYwbzA2GiX7N2ta_itiClRMJLQ0vOxP2tKtaVJRm7pz0O38BrYIUXjAbhDUpActEKQ65IGqIe6BWX2C2c8STH4jttyifvaFmY=\" rel=\"nofollow\" target=\"_blank\"><strong>Bleichmar Fonti &amp; Auld LLP<\/strong><\/a> announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws.<\/p>\n<p>If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0CSKe9LqL0307e8iVCJKJ2KrDB0BAR0eEAGI4_kevd0k-wq4AAyt8obuK392kFj4Fofu_-ssvEjZzz2GVvNYsR7eE2uGWUn-ND9WkI18Hn2rlR0EWLnBC-sj_qiVy6Rjuge2IqPhyqMghah13Wiooeqobl7eFmW_F2hZuZN8EA9iViDMnVz8c9R6kq72NCHLRkHWJZGgpO8PZ8hSdj6gZg==\" rel=\"nofollow\" target=\"_blank\"><strong>https:\/\/www.bfalaw.com\/cases\/adma-biologics-class-action-lawsuit<\/strong><\/a>.<\/p>\n<p>\n        <strong>Why is ADMA Biologics Being Investigated for Securities Fraud? <\/strong>\n      <\/p>\n<p>ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing and developing specialty biologics.\u00a0ADMA Biologics\u2019 flagship product is ASCENIV, a liquid immune globulin solution used to treat Primary Humoral Immunodeficiency in adults and adolescents.<\/p>\n<p>BFA is investigating allegations that ADMA Biologics\u2019 reported 20% revenue growth in 2025 was driven by a channel stuffing scheme to mask deteriorating demand.<\/p>\n<p>\n        <strong>Why did ADMA Biologics\u2019 Stock Drop?<\/strong><\/p>\n<p>On March 24, 2026, Culper Research, an investigative research firm, published a report titled \u201cADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and \u20133% Real Growth in 2025 vs. +20% Reported.\u201d The report revealed, among other things, that in 2025 ADMA Biologics induced one of its distributors to \u201cstock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations.\u201d This allegedly allowed ADMA Biologics to book revenue and \u201creport[] growth that was never there.\u201d According to Culper Research, had ADMA Biologics not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth.<\/p>\n<p>This news caused the price of ADMA Biologics stock to decline $3.96 per share, or 29%, over the course of two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026.<\/p>\n<p>\n        <strong>Click here for more information:<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0CSKe9LqL0307e8iVCJKJ2KrDB0BAR0eEAGI4_kevd0k-wq4AAyt8obuK392kFj4Fofu_-ssvEjZzz2GVvNYsTtIFH0ZyUctIAX0hJOTgVUrkdLwjjXLTakF3DrcnNwzyID-rUMrIexfZhMpI23KxSrnIgP-d6sL7_eCbI8G4ht5aBxgxpe-oT1AE_Qk6sUl9C21HoPJ6cf_7AmSAGJXSA==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>https:\/\/www.bfalaw.com\/cases\/adma-biologics-class-action-lawsuit<\/strong><br \/>\n        <\/a><br \/>\n        <strong>.<\/strong>\n      <\/p>\n<p>\n        <strong>What Can You Do?<\/strong>\n      <\/p>\n<p>If you invested in ADMA Biologics, you may have legal options and are encouraged to submit your information to the firm.<\/p>\n<p>All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.<\/p>\n<p>\n        <strong>Submit your information by visiting:<\/strong>\n      <\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0CSKe9LqL0307e8iVCJKJ2KrDB0BAR0eEAGI4_kevd0k-wq4AAyt8obuK392kFj4Fofu_-ssvEjZzz2GVvNYse8Vm3HM0RF0cYz8uAJ6HGk6GANJ1ZhOO0p6S525uarF3GwZr9x0Vkz3pdki8VRz1V7KrXAnUEStupblSAkJFJ0VoIGAqmvreJf82KWmAjWmYMo9rM4Y8g9h10OSJzRgNg==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>https:\/\/www.bfalaw.com\/cases\/adma-biologics-class-action-lawsuit<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p>Or contact:<br \/>Adam McCall<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aEYaSg8z6-DJwIDIAj4TrVoIAmg--XdvNyE3BUNFtfl1UT4tVU1tH7TehHYNesm9266yUOscrWcR8CBox16-DlzdM6CdwDqpVj1ZyN-ibkI=\" rel=\"nofollow\" target=\"_blank\">adam@bfalaw.com<\/a><br \/>212.789.3619<\/p>\n<p>\n        <strong>Why Bleichmar Fonti &amp; Auld LLP?<\/strong>\n      <\/p>\n<p>BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by <em>Chambers USA<\/em>, <em>The Legal 500<\/em>, and <em>ISS SCAS<\/em>, and its attorneys have been named \u201cElite Trial Lawyers\u201d by the <em>National Law Journal<\/em>, \u201cLitigation Stars\u201d by <em>Benchmark Litigation<\/em>, among the top \u201c500 Leading Plaintiff Financial Lawyers\u201d by <em>Lawdragon<\/em>, \u201cTitans of the Plaintiffs\u2019 Bar\u201d by <em>Law360<\/em> and \u201cSuperLawyers\u201d by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.\u2019s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.<\/p>\n<p>For more information about BFA and its attorneys, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0CSKe9LqL0307e8iVCJKJ2KrDB0BAR0eEAGI4_kevd3oRSZaicMRMFINTfzoMVitdhdeKjiH_3AHubGofnzn6iefgA40tREbdPDF9NbyKbM=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.bfalaw.com<\/a>.<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0CSKe9LqL0307e8iVCJKJ2KrDB0BAR0eEAGI4_kevd0k-wq4AAyt8obuK392kFj4Fofu_-ssvEjZzz2GVvNYsc45Dl9R9VpGIroDe1-YnOTIQEX54HTT0R_R8_4ExM8du0n_dObPTqIgEDef1Lwl0HAxpcdRTNDtEdp0ddheY-KFZwcehPmoMhRj5YM2pZphWf8vTgz2H6PzM56fBHWw2w==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>https:\/\/www.bfalaw.com\/cases\/adma-biologics-class-action-lawsuit<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <em>Attorney advertising. Past results do not guarantee future outcomes.<\/em>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzU0NSM3NTE3OTI2IzIyOTA5OTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2JlY2IzZWYtNjg5OS00Y2NjLWI5OTQtYjBlOWNlN2YwZjZhLTEzMDI1NDUtMjAyNi0wNC0wNi1lbg==\/tiny\/Bleichmar-Fonti-Auld.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BFA Law is investigating ADMA Biologics after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws. NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) &#8212; Leading securities law firm Bleichmar Fonti &amp; Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases\/adma-biologics-class-action-lawsuit. Why is ADMA Biologics Being Investigated for Securities Fraud? ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing and developing specialty biologics.\u00a0ADMA Biologics\u2019 flagship product is ASCENIV, a liquid immune globulin solution used to treat Primary Humoral Immunodeficiency in adults and adolescents. BFA is investigating allegations &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-948989","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BFA Law is investigating ADMA Biologics after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws. NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) &#8212; Leading securities law firm Bleichmar Fonti &amp; Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases\/adma-biologics-class-action-lawsuit. Why is ADMA Biologics Being Investigated for Securities Fraud? ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing and developing specialty biologics.\u00a0ADMA Biologics\u2019 flagship product is ASCENIV, a liquid immune globulin solution used to treat Primary Humoral Immunodeficiency in adults and adolescents. BFA is investigating allegations &hellip; Continue reading &quot;Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-06T10:21:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzU0NSM3NTE3OTI2IzIyOTA5OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law\",\"datePublished\":\"2026-04-06T10:21:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\\\/\"},\"wordCount\":531,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzU0NSM3NTE3OTI2IzIyOTA5OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\\\/\",\"name\":\"Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzU0NSM3NTE3OTI2IzIyOTA5OTU=\",\"datePublished\":\"2026-04-06T10:21:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzU0NSM3NTE3OTI2IzIyOTA5OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzU0NSM3NTE3OTI2IzIyOTA5OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/","og_locale":"en_US","og_type":"article","og_title":"Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law - Market Newsdesk","og_description":"BFA Law is investigating ADMA Biologics after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws. NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) &#8212; Leading securities law firm Bleichmar Fonti &amp; Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https:\/\/www.bfalaw.com\/cases\/adma-biologics-class-action-lawsuit. Why is ADMA Biologics Being Investigated for Securities Fraud? ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing and developing specialty biologics.\u00a0ADMA Biologics\u2019 flagship product is ASCENIV, a liquid immune globulin solution used to treat Primary Humoral Immunodeficiency in adults and adolescents. BFA is investigating allegations &hellip; Continue reading \"Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-06T10:21:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzU0NSM3NTE3OTI2IzIyOTA5OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law","datePublished":"2026-04-06T10:21:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/"},"wordCount":531,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzU0NSM3NTE3OTI2IzIyOTA5OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/","name":"Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzU0NSM3NTE3OTI2IzIyOTA5OTU=","datePublished":"2026-04-06T10:21:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzU0NSM3NTE3OTI2IzIyOTA5OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzU0NSM3NTE3OTI2IzIyOTA5OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-news-adma-biologics-nasdaqadma-drops-29-amid-channel-stuffing-claims-triggering-securities-fraud-investigation-investors-urged-to-contact-bfa-law\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholder News: ADMA Biologics (NASDAQ:ADMA) Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation \u2013 Investors Urged to Contact BFA Law"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/948989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=948989"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/948989\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=948989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=948989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=948989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}